Bepirovirsen sodium is under clinical development by Ionis Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bepirovirsen sodium’s likelihood of approval (LoA) and phase transition for Hepatitis B took place on 23 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bepirovirsen sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bepirovirsen sodium overview

IONIS-HBVRx (ISIS-HBVRx, ISIS-GSK3Rx) is under development for treatment of naive patients with chronic hepatitis B infection. It is administered through subcutaneous injection. The drug candidate targets viral HBV mRNA and reduce the production of viral proteins associated with HBV infection and replication. It is an antisense oligonucleotide developed based on antisense technology platform.

Ionis Pharmaceuticals overview

Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.

Quick View Bepirovirsen sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Bepirovirsen sodium
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.